Table 1.
Qualitative AD study: adult and adolescent demographic and clinical characteristics
Adults (n = 15) | Adolescents (n = 6) | |
---|---|---|
Age (in years) | ||
Mean (SD) | 30.4 (12.9) | 13.0 (1.0) |
Min–max (years) | 19–64 | 12–15 |
Gender, n (%) | ||
Female | 11 (73%) | 3 (50%) |
Race, n (%) | ||
Asian | 8 (53%) | 5 (83%) |
Black | 0 (0%) | 1 (17%) |
Native Hawaiian/Pacific Islander | 1 (7%) | 0 (0%) |
White | 4 (27%) | 0 (0%) |
Biracial | 1 (7%) | 0 (0%) |
Missing | 1 (7%) | 0 (0%) |
Ethnicity, n (%) | ||
Non-Hispanic/non-Latino | 13 (87%) | 6 (100%) |
Education level, n (%) | ||
Elementary/primary school | 0 (0%) | 3 (50%) |
Some high school | 0 (0%) | 3 (50%) |
Some college | 5 (33%) | 0 (0%) |
Associate degree | 1 (7%) | 0 (0%) |
Bachelor’s degree | 7 (47%) | 0 (0%) |
Post-graduate | 1 (7%) | 0 (0%) |
Trade | 1 (7%) | 0 (0%) |
Time since first symptom, n (%) | ||
1–5 years | 4 (27%) | 3 (50%) |
6–10 years | 11 (73%) | 3 (50%) |
Time since diagnosis, n (%) | ||
Less than 1 year | 1 (7%) | 0 (0%) |
1–5 years | 6 (40%) | 3 (50%) |
6–10 years | 8 (53%) | 3 (50%) |
Medications, n (%)a | ||
Triamcinolone | 3 (20%) | 1 (17%) |
Hydrocortisone | 2 (13%) | 1 (17%) |
Tacrolimus | 3 (20%) | 0 (0%) |
Crisaborole | 4 (27%) | 2 (34%) |
Halobetasol | 1 (7%) | 0 (0%) |
Over the counter | 5 (33%) | 2 (34%) |
None | 2 (13%) | 1 (17%) |
Overall health, n (%) | ||
Fair | 3 (20%) | 2 (34%) |
Good | 4 (27%) | 3 (50%) |
Very good | 5 (33%) | 1 (17%) |
Excellent | 2 (13%) | 0 (0%) |
aDoes not sum to 100% as participants could report multiple medications